Document Detail


Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor.
MedLine Citation:
PMID:  20694532     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Foscarnet is an active agent against cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation (HSCT), as well as ganciclovir. We investigated the usefulness of foscarnet in patients who underwent related allogeneic HSCT. Foscarnet was used in 320 patients with a median age of 45 years (range 15-72). The purpose of administration was CMV disease in 65, preemptive use in 248 and prophylaxis in 7. Totally, 194 patients had a history of prior ganciclovir treatment. The reason for foscarnet use was insufficient therapeutic effect of prior ganciclovir in 99, and adverse event including myelosuppression in 95. The response rate in symptom was 52% for the CMV disease patients. Antigenemia disappeared in 77% of the preemptive treatment and improved in 13% of the patients. No outbreak of CMV disease was recognized. The total effectiveness of therapeutic and preemptive use was significantly higher for patients without prior ganciclovir (91 vs. 76%, P = 0.001). Adverse events of grade 3 or higher were recognized in 24%, including electrolyte abnormalities in 11%, neutropenia in 8%, and thrombocytopenia in 8%. Renal damage was only observed in 3% of patients. Foscarnet was concluded to be a safe and effective anti-CMV agent and to be a suitable alternative to ganciclovir.
Authors:
Maiko Asakura; Kazuhiro Ikegame; Satoshi Yoshihara; Shuichi Taniguchi; Takehiko Mori; Tetsuya Etoh; Akiyoshi Takami; Takashi Yoshida; Takahiro Fukuda; Kazuo Hatanaka; Heiwa Kanamori; Toshiaki Yujiri; Yoshiko Atsuta; Hisashi Sakamaki; Ritsuro Suzuki; Hiroyasu Ogawa
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-08-07
Journal Detail:
Title:  International journal of hematology     Volume:  92     ISSN:  1865-3774     ISO Abbreviation:  Int. J. Hematol.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-09     Completed Date:  2010-12-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9111627     Medline TA:  Int J Hematol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  351-9     Citation Subset:  IM    
Affiliation:
Department of HSCT Data Management and Biostatistics, Nagoya University School of Medicine, Higashi-ku, Nagoya, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Cytomegalovirus Infections / drug therapy*,  prevention & control
Drug Evaluation
Family
Female
Foscarnet / therapeutic use*
Ganciclovir / therapeutic use
Hematologic Diseases / complications,  therapy
Hematopoietic Stem Cell Transplantation / adverse effects,  methods*
Humans
Male
Middle Aged
Retrospective Studies
Reverse Transcriptase Inhibitors
Tissue Donors
Transplantation, Homologous
Treatment Outcome
Young Adult
Chemical
Reg. No./Substance:
0/Reverse Transcriptase Inhibitors; 4428-95-9/Foscarnet; 82410-32-0/Ganciclovir

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Rare causes of dystonia parkinsonism.
Next Document:  Optimization of immunomagnetic selection of myeloma cells from bone marrow using magnetic activated ...